Who Will Write the Rules for Global Cannabis Trade?
Photo via Unsplash.
In 2023, the International Narcotics Control Board tracked 568.7 tonnes of medical cannabis moving in formal international trade -- flower, extracts, and intermediate products crossing borders under licenses, quotas, and customs declarations. That's a real commodity flow, comparable in scale to plenty of goods that already operate under global rulebooks. Wheat, pharmaceuticals, and coffee all have established international harmonization frameworks. Cannabis has none of that. What it has instead is three separate governance tracks evolving on their own timelines, built by people who mostly don't coordinate with each other.
The first track is private and technical: standards bodies like ASTM International and ISO writing voluntary specifications for cultivation, testing, and labeling. The second is national trade infrastructure -- individual countries like Germany rebuilding their own import/export plumbing, one customs regulation at a time. The third is the decades-old international treaty system, still the only mechanism with actual legal authority over who can ship cannabis where. None of these three tracks reports to the other two.
The friction this produces isn't mostly about drug policy disagreements, which is the story most coverage defaults to. It's much more mundane than that: a cultivator with product approved under Health Canada's GMP framework can still get held up at a German port because Germany's GACP documentation requirements don't map cleanly onto Canada's paperwork, not because anyone doubts the product's safety. That mismatch -- not ideology -- is the actual bottleneck slowing cross-border trade today. The question worth asking over a five-to-seven-year horizon is whether these three tracks eventually converge into something resembling a shared reference body, or whether the largest trading nations just keep building their own bilateral workarounds faster than any global consensus can form.
The Standards Groundwork Already Laid: ASTM D37 and ISO/TC 353
Photo by Sokmeas UY via Pexels.
The technical groundwork for cannabis standardization didn't start with a government mandate -- it started with an industry conference. In January 2017, the American Public Health Association hosted a gathering that led directly to an organizational meeting at ASTM International's headquarters, and on April 25, 2017, ASTM's board formally approved Committee D37 on Cannabis. That founding sequence matters because it set the pattern that's persisted ever since: cannabis standards in the U.S. have been built from the industry outward, not handed down from a regulator.
Nearly a decade later, D37 is a sprawling operation. It counts more than 1,000 industry stakeholders among its membership and has produced over 1,000 individual cannabis and hemp standards, covering everything from laboratory testing protocols to packaging to its own International Intoxicating Cannabinoids Symbol, a labeling mark meant to flag psychoactive content across product categories. The committee's leadership turnover for the 2026-2027 term -- David Vaillencourt of S3 Collective elected chair, Darwin Millard of CSQ elected vice chair -- is a small but telling signal. Organizations that are still improvising tend to keep the same people in charge indefinitely; orderly succession, with final stakeholder survey results presented in February 2026 in Atlanta ahead of the next full committee meeting set for June 1-3, 2026 in Dallas, is what institutional maturity looks like in practice.
ISO is running a comparable but entirely separate effort. ISO/TC 353 focuses specifically on safety, security, and good production practices for cannabis facilities, with its next meeting scheduled October 26-27, 2026, held virtually. That committee already has one concrete output on the books: IWA 37-3:2022, an international workshop agreement covering good production practices, which functions as a kind of proto-standard while the fuller TC 353 process continues.
It's worth being precise about what these bodies actually are, because it's easy to overstate their reach. ASTM and ISO are voluntary, consensus-based, industry-driven organizations. They have no enforcement power and no relationship to customs authority. A perfectly drafted ASTM standard doesn't get a shipment through a German port any faster unless a government or buyer chooses to recognize it. This layer builds the technical vocabulary everyone eventually needs -- but on its own, it can't move a single gram of product across a border.
Private Certification Is Already Building on Top of These Frameworks
Photo via Pexels.
Private certification schemes are the layer translating those technical standards into something buyers can actually act on, and they're moving fast precisely because they don't need unanimous government buy-in to do it. CSQ 2.0, taking effect in January 2026, is built explicitly on ASTM and ISO frameworks, including the ISO/IEC 17065 and 17067 conformity assessment standards that govern how certification bodies themselves get accredited. The goal is straightforward: a CSQ certification is supposed to mean something recognizable whether the buyer is in Frankfurt, Toronto, or Bangkok, because it's anchored to internationally recognized conformity assessment methodology rather than a one-off proprietary checklist.
This is a familiar playbook in agriculture. GlobalG.A.P. and Fair Trade both built real market credibility as private certification schemes years before any government required them, and buyers adopted them simply because retailers and processors started demanding them as a condition of purchase. Cannabis certification is following the same route: an EU buyer can require CSQ or ASTM-aligned certification in a purchasing contract today, regardless of what treaty-level rules say about anything, because that's a private commercial decision, not a regulatory one.
The speed advantage is real -- private standards bodies don't need a broad coalition of states to agree on anything, just enough market participants to adopt a common reference point. But that same lack of a central mandate is also the weakness. Certification schemes can fragment every bit as easily as they can unify. If the EU market gravitates toward one certification lineage, Canada anchors to another, and emerging buyers across Asia settle on a third, growers end up facing the exact same patchwork compliance burden they have now, just wearing a different, more professional-looking label. Nothing about voluntary adoption guarantees convergence on a single scheme; it just as easily produces three or four competing ones that each claim global relevance.
What this layer is genuinely good at is settling definitional questions -- what counts as GACP-compliant cultivation, what a lab result needs to include to be trusted -- rather than solving the separate, harder problem of actual legal clearance across a border. That second problem still runs entirely through government channels, which is where the treaty system comes back into the picture.
The UN Treaty System Still Controls Who Can Actually Trade
Global medical cannabis production rose sharply from 650 tonnes in 2019 to a peak of nearly 908 tonnes in 2021, before declining to 568.7 tonnes by 2023, falling below its 2019 level.
However sophisticated the technical and certification layers get, the legal authority to move cannabis across a border still sits with the international drug-control treaty system, jointly administered by the INCB, the Commission on Narcotic Drugs, the WHO, and UNODC. No ASTM standard or private certification overrides an import quota or a licensing requirement set under this framework. This is the layer with actual enforcement teeth.
The INCB's own data tells a more complicated growth story than the industry narrative usually suggests. Global medical cannabis production peaked at 907.7 tonnes in 2021 and then fell to 568.7 tonnes by 2023 -- a genuine contraction, not a plateau, and worth taking seriously rather than assuming the trajectory only points upward. Trade remains heavily concentrated: Canada, the UK, and Israel are the top producers; the UK, Canada, and Portugal the leading exporters; Germany, the UK, and Israel the top importers. A handful of countries are effectively running the entire formal international trade, which is itself a structural vulnerability -- any one of them tightening or loosening its rules moves the global numbers meaningfully.
Germany illustrates how this layer actually evolves in practice: not through a new international resolution, but through individual countries modernizing their own machinery. Germany's revised Narcotics Foreign Trade Regulation, published in the Federal Gazette on May 8, 2026, overhauls import and export procedures and introduces an electronic National Drug Control System web portal to handle licensing and documentation. As the single largest importer in the formal medical cannabis trade, Germany didn't wait for a global standards body to streamline its process -- it built its own digital infrastructure and expects trading partners to adapt to it.
That's the pattern worth watching: major importing nations upgrading their own trade mechanics unilaterally, rather than holding out for international consensus. Any future global standards body, whatever form it takes, will have to interface with this treaty-based licensing and quota system, not replace it. Technical harmonization can make compliance paperwork more consistent, but it cannot substitute for the import authorization that only a government, acting under its treaty obligations, can grant.
Why GMP/GACP Harmonization, Not Politics, Is the Real Bottleneck
Ask people working the trade logistics side of this industry what actually slows shipments down, and politics comes up less often than you'd expect. The more common answer is GMP and GACP harmonization -- the plain fact that good manufacturing practice and good agricultural and collection practice mean somewhat different things depending on which regulator wrote the definition. That mismatch, not lingering prohibitionist sentiment, is increasingly identified as the real structural barrier to expanding global cannabis trade.
The problem is compounding as new trade routes open. Producers in Africa, Latin America, and Southeast Asia are entering the formal medical cannabis trade, and each region tends to arrive at its own interpretation of what GACP compliance actually requires. A cultivation operation certified compliant under one jurisdiction's framework can find itself needing a full re-certification process to sell into another, even when the underlying growing practices are functionally identical. This is friction created by divergent paperwork, not divergent agronomy.
There's a useful historical yardstick here: international food safety harmonization efforts. Established decades ago to harmonize food safety standards across wildly different national systems, that process is still actively refining those standards today. Food safety harmonization was not a single breakthrough moment -- it was, and remains, a slow accretion of agreed definitions, committee by committee, product category by product category. Reasoning from that precedent, cannabis harmonization looks like it's on a similarly gradual trajectory rather than heading toward one decisive treaty event.
There's a genuine counter-case for optimism, though. That food-safety harmonization effort started from essentially nothing. Cannabis harmonization has real scaffolding already in place -- ASTM's thousand-plus standards and ISO/TC 353's work, which have already forced international regulators to engage with cannabis-specific science in detail. That existing infrastructure could plausibly compress the timeline relative to the decades-long (and counting) history of comparable food-safety harmonization, even if it doesn't eliminate it.
U.S. rescheduling adds a wrinkle that cuts against easy optimism. If cannabis moves to Schedule III, DEA registrant restrictions mean that, at least initially, only existing registrants would gain access to any new export channels that rescheduling opens up. A major market technically opening doesn't automatically widen the global trading pool -- it may just reshuffle who within the U.S. gets to participate in it, while the international harmonization problem sits untouched.
What a Unified Global Body Would Actually Need to Look Like
Photo by KATRIN BOLOVTSOVA via Pexels.
If a genuinely global cannabinoid standards body does eventually take shape, the most useful precedent for what it would look like isn't a new agency built from scratch -- it's existing international food-safety and trade reference frameworks. Those frameworks didn't replace national food or health regulators. What they did was create reference standards that national systems could point to, which meant a country didn't have to renegotiate the same safety questions bilaterally with every single trading partner. That's a meaningfully lower bar than building a new treaty organization, and it's the more plausible mid-term path here too.
Reasoned from that pattern, the likeliest convergence over the next several years isn't a standalone global cannabis agency but something narrower: ASTM and ISO technical standards maturing into a recognized reference framework that INCB-administered import and export licensing could formally cite, the way food regulators cite established international food-safety references. That would let a shipment's compliance with an ASTM or ISO standard count as evidence toward satisfying a government's GACP or GMP requirement, cutting down on redundant re-certification without requiring anyone to rewrite the underlying treaty framework.
Take that with real caution, though. Treaty bodies in this space operate on consensus among member states whose domestic cannabis policies range from full legalization to strict prohibition. Even a technically sound, scientifically uncontroversial harmonized standard can stall for years for reasons that have nothing to do with its merits -- it just needs one bloc of member states uncomfortable with the broader normalization signal a formal cannabis standard might send. Technical readiness and political readiness are not the same clock.
Whichever path wins, there's a durable business opportunity sitting at the interface: certification consultancies, laboratory-testing networks, and compliance software built on the model of Germany's NDS portal are positioned to profit regardless of how governance ultimately shakes out, because every plausible path still requires someone to verify documentation and translate one jurisdiction's requirements into another's. That's a service business that doesn't need to bet on the outcome to be useful right now.
The realistic expectation for the next three to seven years is incremental bilateral and bloc-level interoperability agreements -- the EU and Canada aligning on specific documentation requirements, say -- rather than one global cannabinoid standards body emerging in a single stroke. That's the same piecemeal pattern seen in nearly every other commodity harmonization effort, and there's no strong evidence cannabis is positioned to skip it.
What's striking about all this is how little coordination is actually happening between the people building it. ASTM committee members gathering in Dallas in June 2026, ISO delegates meeting virtually that October, and German customs officials coding a new web portal are all working on facets of the same underlying problem -- how do you verify and move a regulated agricultural commodity across borders at scale -- without a shared coordinating body telling any of them what to do. The infrastructure for global cannabinoid governance is being assembled in parallel, by people who may never sit in the same room.
That's why the headlines -- a new certification scheme launching, a committee electing new leadership, a country announcing a modernized trade portal -- aren't actually the signal worth tracking. The real tell will be quieter: the first moment an ISO or ASTM standard gets formally cited inside an INCB import or export licensing requirement. That's the interface point where voluntary technical consensus starts acquiring actual legal weight within the treaty system, and it's a far more meaningful marker of harmonization than any announcement of a new committee or certification brand.
Until that interface point shows up, businesses building international cannabis trade strategy should plan on operating in a multi-standard world through at least the rest of this decade. The instinct to wait for a single global rulebook to settle the question is understandable but probably costly -- the decades-long timeline of comparable food-safety harmonization and the treaty system's consensus-bound politics both argue against a tidy convergence arriving on anyone's preferred schedule. Treating compliance flexibility itself as the competitive edge, rather than a cost to be minimized once things settle down, is the more realistic posture for the years immediately ahead.
